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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER169Improving Assessment of Aortic StenosisPhilippe Pibarot, Jean G. Dumesnil
“Degenerative” or calcific aortic stenosis (AS) is a complex, multifaceted, systemic disease that
is not solely limited to the aortic valve, but also includes reduced arterial compliance as well as
alterations of left ventricular (LV) geometry and function. This particular nature of the
disease underscores the need for a more comprehensive evaluation of disease severity going
beyond the standard parameters routinely used to assess stenosis severity (i.e., peak jet
velocity, pressure gradients, valve effective orifice area) or LV function (i.e., LV ejection
fraction). Pibarot and Dumesnil thus propose to review newer approaches to improve the
quantification of disease severity taking into account the inter-relation between the different
valvular, arterial, and ventricular variables that may be responsible for the appearance of
symptoms and/or poorer prognosis in patients with AS.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY181Revascularizing Only Territories With SPECT Defect Reduces MACEYoung-Hak Kim, Jung-Min Ahn, Duk-Woo Park, Hae Geun Song, Jong-Young Lee, Won-Jang Kim,
Sung-Cheol Yun, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Dae Hyuk Moon, Cheol-Hyun Chung,
Jae-Won Lee, Seong-Wook Park, Seung-Jung Park
Kim and colleagues compared the outcomes of patients with ischemia-guided (IG)
revascularization, in which revascularization was performed in the coronary artery matched to
the perfusion abnormality on myocardial perfusion imaging (MPI), with those of non–IG
revascularization. The patients came from a registry of 5,340 patients with multivessel
coronary disease who underwent revascularization. The incidence of major adverse cardiac and
cerebrovascular events (MACCE) was significantly lower in the IG than in the non–IG
group (16% vs. 21%), primarily driven by a lower repeat revascularization rate (9.9% vs. 23%).
Subgroup analysis showed that IG reduced the risk of MACCE in patients who underwent
percutaneous coronary intervention (PCI), but not for coronary artery bypass graft patients.
These results suggest that IG revascularization using MPI in patients with multivessel disease
referred for PCI significantly reduces the risk of repeat revascularization.
Editorial Comment: William S. Weintraub, p. 191(continued on page A-23)
JULY 17, 2012 (continued) A-23ACUTE CORONARY SYNDROMES193Ticagrelor Reduces High-On Clopidogrel Platelet Reactivity More Than PrasugrelDimitrios Alexopoulos, Anastasia Galati, Ioanna Xanthopoulou, Eleni Mavronasiou, George Kassimis,
Konstantinos C. Theodoropoulos, George Makris, Anastasia Damelou, Grigorios Tsigkas, George Hahalis,
Periklis Davlouros
Alexopoulos and colleagues compared the antiplatelet efficacy of ticagrelor and prasugrel in
acute coronary syndrome (ACS) patients with high-on clopidogrel treatment platelet reactivity
(HTPR) after percutaneous coronary intervention (PCI). In a prospective study, 44 ACS
patients with HTPR 24-h post-PCI were randomized to either ticagrelor or prasugrel for
15 days with a crossover to the alternate treatment for another 15 days. The primary endpoint
of platelet reactivity at the end of the treatment period was lower for ticagrelor (32.9 platelet
reactivity unit [PRU]) compared with prasugrel (101.3 PRU). The secondary endpoint of
continued HTPR rate was 0% for ticagrelor and 2.4% for prasugrel. In patients with ACS,
exhibiting HTPR, ticagrelor produces a significantly higher platelet inhibition compared with
prasugrel.CARDIOVASCULAR RISK200Serum Levels of FGF-23 Linked to Cardiovascular Risk0
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Quarle 1 Quarle 2 Quarle 3 Quarle 4Joachim H. Ix, Ronit Katz, Bryan R. Kestenbaum, Ian H. de Boer, Michel Chonchol, Kenneth J. Mukamal,
Dena Rifkin, David S. Siscovick, Mark J. Sarnak, Michael G. Shlipak
Fibroblast growth factor (FGF)-23 is a hormone secreted into blood from bone osteocytes. It
induces urinary phosphorus excretion and inhibits activation of vitamin D. Ix and colleagues
studied the association of FGF-23 with death, heart failure (HF), and cardiovascular disease
in persons 65 years of age. Both lower estimated glomerular filtration rate and higher urine
albumin to creatinine ratio were associated with higher FGF-23 at baseline. During a median
10.5 years of follow-up, FGF-23 concentrations were associated with each of the outcomes of
interest: death, incident heart failure, and cardiovascular events. The associations were
consistently stronger for those with chronic kidney disease (CKD). FGF-23 is independently
associated with all-cause death and incident HF in older persons, particularly those with
CKD.HEART FAILURE208Higher Dose of Beta-Blocker Linked to Better Outcomes for CHF PatientsMona Fiuzat, Daniel Wojdyla, Dalane Kitzman, Jerome Fleg, Steven J. Keteyian, William E. Kraus,
Ileana L. Piña, David Whellan, Christopher M. O’Connor
Beta-blockers (BBs) reduce morbidity and mortality in chronic heart failure (HF) patients
with reduced ejection fraction, but it is unclear whether higher doses are better. Fiuzat and
colleagues examined how baseline BB dose affected outcomes in a HF trial with BB dose at
baseline standardized using carvedilol equivalents. There was a significant inverse relationship
between BB dose and all-cause death or hospitalization with a linear benefit up to the 50 mg
daily dose. These results support recommendations that titrating doses up to 50 mg per day
of carvedilol equivalents improves outcomes in patients with systolic dysfunction.(continued on page A-24)
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-1 Romain Capoulade, Marie-Annick Clavel, Jean G. Dumesnil, Kwan L. Chan, Koon K. Teo,
James W. Tam, Nancy Côté, Patrick Mathieu, Jean-Pierre Després, Philippe Pibarot,
on behalf of the ASTRONOMER Investigators
This pre-defined substudy of patients enrolled in the ASTRONOMER trial examined the
relationship between the metabolic syndrome (MetS) and the progression of aortic stenosis.
Aortic stenosis (AS) progression rate was measured by calculating the annualized increase in
peak aortic jet velocity measured by Doppler-echocardiography. Patients with MetS did have
faster stenosis progression. Statin therapy did not slow AS progression in patients with or
without MetS.DISEASE OF THE AORTA
224mpact of Pregnancy on Aortic Growth Rate and Mortality
in Women With Marfan SyndromeRyan T. Donnelly, Nelangi M. Pinto, Irene Kocolas, Anji T. Yetman
There is a paucity of data on peripartum and long-term clinical outcomes in women with
Marfan syndrome who are followed prospectively during pregnancy. Donnelly and colleagues
report on 98 women with Marfan syndrome followed in an aortopathy clinic; 72%
experienced a total of 199 pregnancies. No woman experienced aortic dissection nor required
cardiac surgery during pregnancy. Aortic growth rate increased during pregnancy and did not
return to baseline afterwards. The prevalence of both aortic dissection, and the risk of elective
aortic surgery during long-term follow-up was higher in women who had a prior pregnancy.
These results show that there is a low incidence of aortic complications during pregnancy in
women with Marfan syndrome and an aortic diameter 4.5 cm. However, pregnancy does
increase the long-term risk of aortic complications.Editorial Comment: Barbara J. M. Mulder, Lilian J. Meijboom, p. 230
